COVID-20

Cocrystal Pharma’s SARS-CoV-2 3CL Protease Lead CDI-45205 Demonstrates Broad-Spectrum Activity Against the SARS-CoV-2 Delta and Gamma Variants

Retrieved on: 
Thursday, July 29, 2021
Coronaviridae, Variants of SARS-CoV-2, Sarbecovirus, Zoonoses, Severe acute respiratory syndrome coronavirus 2, 3C-like protease, SARS-CoV-2 lineage B.1.617, SARS-CoV-2 Beta variant, SARS-CoV-2 Delta variant, Middle East respiratory syndrome–related coronavirus, COVID-20

BOTHELL, Wash., July 29, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces that its SARS-CoV-2 3CL protease lead CDI-45205 and several analogs showed potent in vitro activity against the SARS-CoV-2 Delta (India/B.1.617.2) and Gamma (Brazil/P.1) variants.

Key Points: 
  • BOTHELL, Wash., July 29, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces that its SARS-CoV-2 3CL protease lead CDI-45205 and several analogs showed potent in vitro activity against the SARS-CoV-2 Delta (India/B.1.617.2) and Gamma (Brazil/P.1) variants.
  • Cocrystal previously announced that CDI-45205 and analogs exhibited broad-spectrum activity against the SARS-CoV-2 Alpha (United Kingdom/B.1.1.7) and Beta (South African/B.1.351) variants, surpassing the activity observed with the Wuhan strain.
  • The broad-spectrum activity against these SARS-CoV-2 variants is highly encouraging as CDI-45205 previously demonstrated excellent in vivo efficacy in a MERS-CoV-2 infected animal model.
  • The Company continues to develop SARS-CoV-2 oral protease inhibitors and replication inhibitors using its proprietary drug discovery platform technology.

New Publications Confirm Paragon Genomics CleanPlex® SARS-CoV-2 Panel Enables Accurate Identification of Variants of Concern

Retrieved on: 
Wednesday, July 28, 2021
Coronaviridae, Variants of SARS-CoV-2, Sarbecovirus, COVID-19 pandemic in India, COVID-19, SARS-CoV-2 lineage B.1.617, Severe acute respiratory syndrome coronavirus 2, SARS-CoV-2 Alpha variant, SARS-CoV-2 Delta variant, Severe acute respiratory syndrome coronavirus, COVID-20

The analyses enabled the researchers to assign the viral genomes to SARS-CoV-2 lineages and confirm the presence of the B.1.1.7 variant.

Key Points: 
  • The analyses enabled the researchers to assign the viral genomes to SARS-CoV-2 lineages and confirm the presence of the B.1.1.7 variant.
  • A third study, from a Paragon Genomics public health laboratory customer, describes how the CleanPlex SARS-CoV-2 Panel enabled the early identification of one of the first confirmed cases of the B.1.617.2 Delta variant in Brazil.
  • Paragon Genomics' CleanPlex SARS-CoV-2 technology has powered variant detection and tracking since the virus first appeared.
  • In March 2020, the company launched the CleanPlex SARS-CoV-2 Panel whole genome SARS-CoV-2 sequencing on Illumina and MGI Tech sequencing platforms.

Delta Variant Testing Device Developed by UAT Group Affiliate, Bacter Scientific

Retrieved on: 
Thursday, July 22, 2021
Coronaviridae, Sarbecovirus, Variants of SARS-CoV-2, COVID-19, Severe acute respiratory syndrome coronavirus 2, Zoonoses, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome, COVID-20

Each new copy of a virus contains tiny copying errors or variations in its genome which is what is referred to as a variant.

Key Points: 
  • Each new copy of a virus contains tiny copying errors or variations in its genome which is what is referred to as a variant.
  • Novi is the only hand-held, portable, battery powered device with built-in redundancy, delivering the most accurate results of any testing device.
  • A US government SARS-CoV-2 Interagency Group (SIG) developed Variant Classifications that defines three classes of SARS-CoV-2 variants.
  • Bacter Scientific does not assume the obligation to update any forward-looking statement, except as required by applicable law.

Paragon Genomics Highlights Year of Rapid Growth Fueled by Broad Acceptance of Its CleanPlex® SARS-CoV-2 Research and Surveillance Products

Retrieved on: 
Tuesday, April 27, 2021
Coronaviridae, Sarbecovirus, Zoonoses, Bat virome, Variants of SARS-CoV-2, Severe acute respiratory syndrome, Severe acute respiratory syndrome coronavirus, Illumina, Inc., COVID-20

"\nParagon Genomics\' CleanPlex SARS-CoV-2 technology has powered variant detection and tracking since the virus first appeared.

Key Points: 
  • "\nParagon Genomics\' CleanPlex SARS-CoV-2 technology has powered variant detection and tracking since the virus first appeared.
  • In March 2020, the company launched the CleanPlex SARS-CoV-2 Panel whole genome SARS-CoV-2 sequencing on Illumina and MGI Tech sequencing platforms.
  • "\nParagon Genomics CleanPlex SARS-CoV-2 Emerging Variant Panel Add-On is designed to be used with existing CleanPlex SARS-CoV-2 products to maintain uniform genomic coverage for variant calling and identification.
  • The company designs and manufactures high performance and ultra-multiplexed amplicon NGS library preparation products for analyzing difficult, clinically relevant samples.

Seegene begins exporting its latest COVID-19 variant tests around the world to help contain spread of pandemic

Retrieved on: 
Monday, April 12, 2021
Articles, Variants of SARS-CoV-2, Health, Occupational safety and health, COVID-19 pandemic in the United Kingdom, Lineage B.1.1.7, COVID-19, 501.V2 variant, Pandemic, Variant of concern, COVID-20

The variant test can detect virus variants including B.1.1.7, B.1.351 and P.1.

Key Points: 
  • The variant test can detect virus variants including B.1.1.7, B.1.351 and P.1.
  • "Seegene will continue to closely monitor developments on the virus variant front and provide additional variant tests to help contain the spread of the virus and put an end to the pandemic.
  • the so-called "UK variant" has proven to be not only more contagious but also deadlier, raising alarm across the world.
  • Seegene continues to set new standards in MDx providing new, cost-effective innovations.\nView original content to download multimedia: http://www.prnewswire.com/news-releases/seegene-begins-exporting-its-lat...\n'